CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 370,212 enrolled
Drug / intervention
Escitalopram +10 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04446039
NCT04446039N/ACompleted
CompareCT.gov

Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data

Pfizer·observational·Posted Jun 24, 2020·Updated Dec 9, 2024

In Brief

An observational study evaluating Escitalopram, Paroxetine, and 9 other interventions for Major Depression. Completed, enrolled 370,212 participants across 1 site.

Detailed Summary

The primary purpose of this study is to investigate medication utilization pattern and risk of adverse outcomes among commonly used antidepressants by using nationwide claims database, in order to assess overall clinical benefit of antidepressant therapy in real-world practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depression
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 24, 2020
Enrollment StartJul 4, 2022
Primary CompletionNov 3, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.0 years ago

Interventions

Escitalopramdrug

Treatment for depression

Paroxetinedrug

Treatment for depression

Fluoxetinedrug

Treatment for depression

Mirtazapinedrug

Treatment for depression

Duloxetinedrug

Treatment for depression

Sertralinedrug

Treatment for depression

Venlafaxinedrug

Treatment for depression

Tianeptinedrug

Treatment for depression

Vortioxetinedrug

Treatment for depression

Desvenlafaxinedrug

Treatment for depression

Bupropiondrug

Treatment for depression